Smith Kline & French Laboratories Limited

David A Owen

Charon R Ganellin

Robert John Ife

The present invention relates to the use of certain indolone derivatives in particular, 4-(2-di-n-propyl-aminoethyl)-2-(3H)-indolone in a method of treatment of Parkinsons disease.

Producing anxiolytic activity and treating depression with 3(H)-indolones

Treatment of Parkinsons disease

The compounds are isoureas and isothioureas which have an O- or S-alkylpyrimidone substituent and which are histamine H.sub.2 -antagonists and antiinflammatory agents. A specific compound of this invention is 2-[5-(O-isoureido)pentylamino]-5-(6-methyl-3-pyridylmethyl)-4-pyrimidone.

2-substituted alkylaminopyrimidones useful as H.sub.2 -antagonists and

The compounds are isoureas and isothioureas which have an O- or S- alkylpyrimidone substituent and which are histamine H.sub.2 -antagonists and antiinflammatory agents. A specific compound of this invention is 2-[5-(O-isoureido)pentylamino]-5-(6-methyl-3-pyridylmethyl)-4-pyrimidone.

2-Substituted alkylaminopyrimidones

The compounds are isoureas and isothioureas which have an O- or S- alkylpyrimidone substituent and which are histamine H.sub.2 -antagonists and antiinflammatory agents. A specific compound of this invention is 2-[5-(O-isoureido)pentylamino]-5-(6-methyl-3-pyridyl-methyl)-4-pyrimidone.

Growing community of inventors

Welwyn Garden City, United Kingdom

David A Owen